Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 11/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.43 |
| ▸ | METAP1 | P53582 | 2/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13866811 | 0.77 | DRD2 (0.49) | — | |
| SCHEMBL1025843 | 0.77 | DRD2 (0.49) | — | |
| SCHEMBL13241438 | 0.77 | ACHE (0.44) | METAP1PARP10PARP11 | |
| SCHEMBL4045125 | 0.77 | PSEN1 (0.42) | — | |
| SCHEMBL13241439 | 0.77 | ACHE (0.44) | METAP1PARP10PARP11 | |
| SCHEMBL13866808 | 0.74 | IDO1 (0.44) | — | |
| SCHEMBL2485525 | 0.74 | IDO1 (0.44) | — | |
| SCHEMBL6317426 | 0.74 | IDO1 (0.44) | — | |
| SCHEMBL3033723 | 0.73 | ALDH1A1 (0.49) | TDP2TDP1L3MBTL1 | |
| SCHEMBL3028797 | 0.73 | ALDH1A1 (0.49) | TDP2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| EP-1268412-B1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK CANADA INC. (CA) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | BACE1, BACE2, PSEN2 | PNMT 2453/4885ADRA2A 4240/4885ADRA2B 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.